ConforMIS

ConforMIS, Inc. is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. It operates through the following geographical segments: United States, Germany, and Rest of the World. The firm's products include iUni, iDuo, iTotal CR, and iTotal. The company was founded by Philipp Lang in 2004 and is headquartered in Billerica, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which it refers to as personalized, individualized, or sometimes as customized, to fit each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers.

Conformis Settles Medacta Litigation Related to Patient-Specific Instruments Conformis Settles Medacta Litigation Related to Patient-Specific Instruments

Conformis, Inc. Announces Settlement of Medacta Patent Litigation

Conformis, Inc. (NASDAQ:CFMS ) Q3 2022 Results Conference Call November 2, 2022 4:30 PM ET Company Participants Mark Augusti - President and CEO Bob Howe - CFO and Treasurer Conference Call Participants Eric Anderson - Cowen Caitlin Cronin - Canaccord Genuity Operator Good morning and welcome to the Third Quarter 2022 Earnings Conference Call for Conformis, Inc. My name is Shannon, and I will be your conference operator today. All lines have been placed on listen-only mode to prevent any background noise.

Conformis, Inc. (CFMS) Q3 2022 Earnings Call Transcript

ConforMIS (CFMS) delivered earnings and revenue surprises of -14.29% and 0.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ConforMIS (CFMS) Reports Q3 Loss, Misses Revenue Estimates

BILLERICA, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the third quarter ended September 30, 2022.

Conformis Reports Third Quarter 2022 Financial Results

BILLERICA, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the third quarter ended September 30, 2022, after the market closes on Wednesday, November 2, 2022.

Conformis, Inc. to Announce Financial Results for Its Third Quarter 2022

New design adds increasingly more common tri-taper femoral stem design and direct anterior approaches to the expanding Conformis family of Personalized Total Hip Arthroplasty implants New design adds increasingly more common tri-taper femoral stem design and direct anterior approaches to the expanding Conformis family of Personalized Total Hip Arthroplasty implants

Conformis Actera™ Hip System Receives 510(k) Clearance from the U.S. Food and Drug Administration

BILLERICA, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate in the H.C. Wainwright & Co. 24th Annual Global Investment Conference.

Conformis, Inc. to Participate in the H.C. Wainwright & Co. 24th Annual Global Investment Conference

Start Time: 08:30 January 1, 0000 8:57 AM ET Conformis, Inc. (NASDAQ:CFMS ) Q2 2022 Earnings Conference Call August 09, 2022, 08:30 AM ET Company Participants Mark Augusti - President and CEO Bob Howe - CFO and Treasurer Conference Call Participants Eric Anderson - Cowen Steven Lichtman - Oppenheimer Caitlin Cronin - Canaccord Genuity Operator Good morning, and welcome to the Second Quarter 2022 Earnings Conference Call for Conformis, Inc. My name is Justin, and I will be your conference operator today. All lines have been placed on mute to prevent any background noise.

Conformis, Inc. (CFMS) CEO Mark Augusti on Q2 2022 Results - Earnings Call Transcript

BILLERICA, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2022.

Conformis Reports Second Quarter 2022 Financial Results

Agreement enables interested Vizient members, including academic medical centers, acute care facilities, and ambulatory surgery centers (ASCs), to purchase Conformis knee and hip replacement solutions, including its new Image-to-Implant® Platinum Services℠ Program Agreement enables interested Vizient members, including academic medical centers, acute care facilities, and ambulatory surgery centers (ASCs), to purchase Conformis knee and hip replacement solutions, including its new Image-to-Implant® Platinum Services℠ Program

Conformis Announces New Agreement with Vizient for Personalized Orthopedic Implants

BILLERICA, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate in the Canaccord Genuity 42nd Annual Growth Conference.

Conformis, Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference

BILLERICA, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the second quarter ended June 30, 2022, after the market closes on Monday, August 8, 2022.

Conformis, Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022

BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate in the H.C. Wainwright (HCW) Global Investment Conference.

Conformis, Inc. to Participate in the H.C. Wainwright Global Investment Conference

Conformis, Inc. (NASDAQ:CFMS ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Mark Augusti - President and Chief Executive Officer Bob Howe - Chief Financial Officer Conference Call Participants Steven Lichtman - Oppenheimer & Company Josh Jennings - Cowen Operator Good morning, and welcome to the First Quarter 2022 Earnings Conference Call for Conformis. My name is Michelle, and I'll be your conference operator today.

Conformis, Inc. (CFMS) CEO Mark Augusti on Q1 2022 Results - Earnings Call Transcript

BILLERICA, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2022.

Conformis Reports First Quarter 2022 Financial Results

BILLERICA, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today it will release its financial results for the first quarter ended March 31, 2022, before the market opens on Wednesday, May 4, 2022, at approximately 7:00 a.m. Eastern Time.

Conformis, Inc. to Release First Quarter 2022 Financial Results on May 4, 2022

BILLERICA, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced today that Michael Fillion has joined the Company as its Chief Operating Officer.

Conformis, Inc. Appoints Michael Fillion as Chief Operating Officer

The partnership, announced at the 2022 AAOS conference, will enable patients that have selected a fully personalized Conformis implant – through the company's Image-to-Implant Platinum Services Program – access to flexible payment options The partnership, announced at the 2022 AAOS conference, will enable patients that have selected a fully personalized Conformis implant – through the company's Image-to-Implant Platinum Services Program – access to flexible payment options

Conformis Partners with Synchrony to Offer CareCredit Financial Services to Orthopedic Patients

BILLERICA, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Denise Pedulla has joined the Company as its Chief Legal Officer and Corporate Secretary.

Conformis, Inc. Appoints Denise Pedulla as Chief Legal Officer and Corporate Secretary

BILLERICA, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced today that Gary P. Fischetti has been nominated to stand for election to the Company's Board of Directors at the Company's 2022 Annual Meeting of Stockholders, scheduled to be held on May 4, 2022. Mr. Fischetti will replace Richard Meelia, who will be retiring from the Board immediately prior to the Annual Meeting.

Gary Fischetti nominated to join Conformis' Board of Directors

Conformis Inc's (NASDAQ: CFMS) Q4 revenues decreased 8% Y/Y to $15.4 million, missing the consensus of $15.61 million. The decrease is primarily due to deferred and rescheduled elective surgeries due to increased COVID-19 cases associated with the Delta and Omicron variants.

Conformis' Q4 Miss Street View As Earnings Impacted By Surge In COVID-19 Cases

Conformis, Inc.'s (CFMS) CEO Mark Augusti on Q4 2021 Results - Earnings Call Transcript

BILLERICA, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ended December 31, 2021.

Conformis, Inc. Reports Fourth Quarter and Year End 2021 Financial Results

American Battery Technology Company

Gamida Cell Ltd

Can these penny stocks make gains moving forward? The post Popular Penny Stocks to Know About as January Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Popular Penny Stocks to Know About as January Ends

BILLERICA, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that as mentioned on its Business Update call on January 6, 2022, it will release its financial results for the fourth quarter and fiscal year ended December 31, 2021, after the market closes on Wednesday, March 2, 2022, at approximately 4:00 p.m. Eastern Time.

News for ConforMIS Stock (CFMS)